Applied pharmacology in percutaneous coronary intervention: You can't fight mother nature

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Medical Device Technology

Background:

• Second-generation drug-eluting stents (DES) represent advancements in treating atherosclerotic cardiovascular disease.
• Previous generations of DES demonstrated variable outcomes related to target vessel size.
• Understanding persistent disparities in DES performance across different vessel diameters is crucial for clinical practice.

Discussion:

• Differential outcomes related to target vessel diameter persist despite second-generation DES technology.
• The primary driver of these differences appears to be the need for target vessel revascularization (TVR).
• Hard atherosclerotic cardiovascular disease outcomes, including mortality and myocardial infarction, show no significant differences across vessel diameters.

Key Insights:

• Target vessel diameter remains a significant factor influencing outcomes with current drug-eluting stent technology.
• The increased need for target vessel revascularization in smaller vessels warrants further investigation.
• Current second-generation DES provide comparable protection against major adverse cardiovascular events (MACE) irrespective of vessel size.

Outlook:

• Future research should explore non-mechanistic treatment strategies tailored to patient characteristics to address TVR disparities.
• Personalized treatment approaches may be necessary to optimize outcomes in specific patient subsets.
• Continued evaluation of novel stent designs and adjunctive therapies is needed to further minimize vessel-specific variations.